1
|
Aguirre-Ruiz P, Ariceta B, Viguria MC, Zudaire MT, Blasco-Iturri Z, Arnedo P, Aguilera-Diaz A, Jauregui A, Mañú A, Prosper F, Mateos MC, Fernández-Mercado M, Larráyoz MJ, Redondo M, Calasanz MJ, Vázquez I, Bandrés E. Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms. J Clin Med 2020; 9:jcm9123818. [PMID: 33255857 PMCID: PMC7760908 DOI: 10.3390/jcm9123818] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 11/20/2020] [Accepted: 11/23/2020] [Indexed: 12/30/2022] Open
Abstract
Patients with myeloid neoplasms who relapsed after allogenic hematopoietic stem cell transplant (HSCT) have poor prognosis. Monitoring of chimerism and specific molecular markers as a surrogate measure of relapse is not always helpful; therefore, improved systems to detect early relapse are needed. We hypothesized that the use of next generation sequencing (NGS) could be a suitable approach for personalized follow-up post-HSCT. To validate our hypothesis, we analyzed by NGS, a retrospective set of peripheral blood (PB) DNA samples previously evaluated by high-sensitive quantitative PCR analysis using insertion/deletion polymorphisms (indel-qPCR) chimerism engraftment. Post-HCST allelic burdens assessed by NGS and chimerism status showed a similar time-course pattern. At time of clinical relapse in 8/12 patients, we detected positive NGS-based minimal residual disease (NGS-MRD). Importantly, in 6/8 patients, we were able to detect NGS-MRD at time points collected prior to clinical relapse. We also confirmed the disappearance of post-HCST allelic burden in non-relapsed patients, indicating true clinical specificity. This study highlights the clinical utility of NGS-based post-HCST monitoring in myeloid neoplasia as a complementary specific analysis to high-sensitive engraftment testing. Overall, NGS-MRD testing in PB is widely applicable for the evaluation of patients following HSCT and highly valuable to personalized early treatment intervention when mixed chimerism is detected.
Collapse
Affiliation(s)
- Paula Aguirre-Ruiz
- Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, 31008 Pamplona, Navarra, Spain; (P.A.-R.); (B.A.); (Z.B.-I.); (A.M.); (M.F.-M.); (M.J.L.); (M.J.C.)
| | - Beñat Ariceta
- Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, 31008 Pamplona, Navarra, Spain; (P.A.-R.); (B.A.); (Z.B.-I.); (A.M.); (M.F.-M.); (M.J.L.); (M.J.C.)
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Navarra, Spain; (M.C.V.); (M.T.Z.); (A.A.-D.); (F.P.); (M.C.M.); (M.R.)
| | - María Cruz Viguria
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Navarra, Spain; (M.C.V.); (M.T.Z.); (A.A.-D.); (F.P.); (M.C.M.); (M.R.)
- Hematology Department, Complejo Hospitalario de Navarra, 31008 Pamplona, Navarra, Spain; (P.A.); (A.J.)
| | - María Teresa Zudaire
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Navarra, Spain; (M.C.V.); (M.T.Z.); (A.A.-D.); (F.P.); (M.C.M.); (M.R.)
- Hematology Department, Complejo Hospitalario de Navarra, 31008 Pamplona, Navarra, Spain; (P.A.); (A.J.)
| | - Zuriñe Blasco-Iturri
- Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, 31008 Pamplona, Navarra, Spain; (P.A.-R.); (B.A.); (Z.B.-I.); (A.M.); (M.F.-M.); (M.J.L.); (M.J.C.)
| | - Patricia Arnedo
- Hematology Department, Complejo Hospitalario de Navarra, 31008 Pamplona, Navarra, Spain; (P.A.); (A.J.)
| | - Almudena Aguilera-Diaz
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Navarra, Spain; (M.C.V.); (M.T.Z.); (A.A.-D.); (F.P.); (M.C.M.); (M.R.)
- Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), 31008 Pamplona, Navarra, Spain
| | - Axier Jauregui
- Hematology Department, Complejo Hospitalario de Navarra, 31008 Pamplona, Navarra, Spain; (P.A.); (A.J.)
| | - Amagoia Mañú
- Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, 31008 Pamplona, Navarra, Spain; (P.A.-R.); (B.A.); (Z.B.-I.); (A.M.); (M.F.-M.); (M.J.L.); (M.J.C.)
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Navarra, Spain; (M.C.V.); (M.T.Z.); (A.A.-D.); (F.P.); (M.C.M.); (M.R.)
| | - Felipe Prosper
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Navarra, Spain; (M.C.V.); (M.T.Z.); (A.A.-D.); (F.P.); (M.C.M.); (M.R.)
- Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), 31008 Pamplona, Navarra, Spain
- Hematology Department, Clinica Universidad de Navarra (CUN), 31008 Pamplona, Navarra, Spain
| | - María Carmen Mateos
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Navarra, Spain; (M.C.V.); (M.T.Z.); (A.A.-D.); (F.P.); (M.C.M.); (M.R.)
- Hematology Department, Complejo Hospitalario de Navarra, 31008 Pamplona, Navarra, Spain; (P.A.); (A.J.)
| | - Marta Fernández-Mercado
- Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, 31008 Pamplona, Navarra, Spain; (P.A.-R.); (B.A.); (Z.B.-I.); (A.M.); (M.F.-M.); (M.J.L.); (M.J.C.)
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Navarra, Spain; (M.C.V.); (M.T.Z.); (A.A.-D.); (F.P.); (M.C.M.); (M.R.)
- Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), 31008 Pamplona, Navarra, Spain
| | - María José Larráyoz
- Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, 31008 Pamplona, Navarra, Spain; (P.A.-R.); (B.A.); (Z.B.-I.); (A.M.); (M.F.-M.); (M.J.L.); (M.J.C.)
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Navarra, Spain; (M.C.V.); (M.T.Z.); (A.A.-D.); (F.P.); (M.C.M.); (M.R.)
| | - Margarita Redondo
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Navarra, Spain; (M.C.V.); (M.T.Z.); (A.A.-D.); (F.P.); (M.C.M.); (M.R.)
- Hematology Department, Complejo Hospitalario de Navarra, 31008 Pamplona, Navarra, Spain; (P.A.); (A.J.)
| | - María José Calasanz
- Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, 31008 Pamplona, Navarra, Spain; (P.A.-R.); (B.A.); (Z.B.-I.); (A.M.); (M.F.-M.); (M.J.L.); (M.J.C.)
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Navarra, Spain; (M.C.V.); (M.T.Z.); (A.A.-D.); (F.P.); (M.C.M.); (M.R.)
| | - Iria Vázquez
- Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, 31008 Pamplona, Navarra, Spain; (P.A.-R.); (B.A.); (Z.B.-I.); (A.M.); (M.F.-M.); (M.J.L.); (M.J.C.)
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Navarra, Spain; (M.C.V.); (M.T.Z.); (A.A.-D.); (F.P.); (M.C.M.); (M.R.)
- Correspondence: (I.V.); (E.B.); Tel.: +34-948194700-1000 (I.V.)
| | - Eva Bandrés
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Navarra, Spain; (M.C.V.); (M.T.Z.); (A.A.-D.); (F.P.); (M.C.M.); (M.R.)
- Hematology Department, Complejo Hospitalario de Navarra, 31008 Pamplona, Navarra, Spain; (P.A.); (A.J.)
- Correspondence: (I.V.); (E.B.); Tel.: +34-948194700-1000 (I.V.)
| |
Collapse
|
2
|
Duek A, Trakhtenbrot L, Avigdor A, Nagler A, Leiba M. Multiple Myeloma Presenting in Patients Younger than 50 Years of Age: A Single Institution Experience. Acta Haematol 2020; 144:58-65. [PMID: 32512574 DOI: 10.1159/000507414] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Accepted: 03/21/2020] [Indexed: 01/07/2023]
Abstract
INTRODUCTION Multiple myeloma (MM) is uncommon in persons younger than 50 years of age. The presenting features in this age group are unclear. METHODS We analyzed a cohort of patients <50 years of age with MM treated in our center. RESULTS Twenty-three patients at a median age of 41.5 years (range 27-49) were analyzed. Patients presented at International Staging System (ISS) I-II (79%), had high frequency of bone lytic lesions (89%), extramedullary disease (26%), light-chain myeloma (45%), and translocation t(11;14) (68%). The subpopulation of patients carrying t(11;14) were younger (p = 0.025). This subgroup had higher bone marrow infiltration of plasma cells (75 vs. 47.5%), higher incidence of proteinuria (2.9 vs. 0.19 g/day), and poorer response to therapy: 85.7% of patients achieving complete/very good partial remission after induction therapy did not have t(11;14). A trend toward inferior progression-free survival (PFS) was observed in patients with t(11; 14) compared to patients without this translocation (median PFS 18 and 36 months, respectively). DISCUSSION/CONCLUSION Translocation t(11; 14) seems to be more prevalent in young myeloma patients. Young myeloma patients and especially those who harbor translocation t(11; 14) may represent a distinct clinical entity that confers a poor outcome.
Collapse
Affiliation(s)
- Adrian Duek
- Division of Hematology and Bone Marrow Transplantation, and the Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
- Division of Hematology, Assuta Ashdod University Hospital, and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
| | - Luba Trakhtenbrot
- Division of Hematology and Bone Marrow Transplantation, and the Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Abraham Avigdor
- Division of Hematology and Bone Marrow Transplantation, and the Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Arnon Nagler
- Division of Hematology and Bone Marrow Transplantation, and the Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Merav Leiba
- Division of Hematology and Bone Marrow Transplantation, and the Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Israel,
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel,
- Division of Hematology, Assuta Ashdod University Hospital, and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel,
| |
Collapse
|
3
|
Leiba M, Duek A, Amariglio N, Avigdor A, Benyamini N, Hardan I, Zilbershats I, Ganzel C, Shevetz O, Novikov I, Cohen Y, Ishoev G, Rozic G, Nagler A, Trakhtenbrot L. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable? Genes Chromosomes Cancer 2016; 55:710-8. [DOI: 10.1002/gcc.22372] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2016] [Revised: 05/02/2016] [Accepted: 05/03/2016] [Indexed: 12/20/2022] Open
Affiliation(s)
- Merav Leiba
- Division of Hematology and Bone Marrow Transplantation; and the Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University; Tel Aviv Israel
| | - Adrian Duek
- Division of Hematology and Bone Marrow Transplantation; and the Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University; Tel Aviv Israel
| | - Ninette Amariglio
- Division of Hematology and Bone Marrow Transplantation; and the Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University; Tel Aviv Israel
| | - Abraham Avigdor
- Division of Hematology and Bone Marrow Transplantation; and the Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University; Tel Aviv Israel
| | - Noam Benyamini
- Department of Hematology and Bone Marrow Transplantation; Rambam Health Care Campus; Haifa Israel
| | - Izhar Hardan
- Department of Hematology; Meir Medical Center; Kfar Saba Israel
| | | | - Chezi Ganzel
- Department of Hematology; Shaare Zedek Medical Center; Jerusalem Israel
| | - Olga Shevetz
- Department of Hematology; Kaplan Medical Center; Rehovot Israel
| | - Ilya Novikov
- Biostatistical Unit; Gertner Institute of Epidemiology and Health Policy Research; Ramat Gan Israel
| | - Yossi Cohen
- Department of Hematology; Laniyado Hospital; Netanya Israel
| | - Galina Ishoev
- Division of Hematology and Bone Marrow Transplantation; and the Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University; Tel Aviv Israel
| | - Gabriela Rozic
- Division of Hematology and Bone Marrow Transplantation; and the Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University; Tel Aviv Israel
| | - Arnon Nagler
- Division of Hematology and Bone Marrow Transplantation; and the Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University; Tel Aviv Israel
| | - Luba Trakhtenbrot
- Division of Hematology and Bone Marrow Transplantation; and the Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University; Tel Aviv Israel
| |
Collapse
|
4
|
Oral lichen planus patients exhibit consistent chromosomal numerical aberrations: A follow-up analysis. Head Neck 2015; 38 Suppl 1:E741-6. [DOI: 10.1002/hed.24086] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2013] [Revised: 11/12/2014] [Accepted: 04/14/2015] [Indexed: 11/07/2022] Open
|
5
|
Pajor G, Kajtár B, Pajor L, Alpár D. State-of-the-art FISHing: automated analysis of cytogenetic aberrations in interphase nuclei. Cytometry A 2012; 81:649-63. [PMID: 22696411 DOI: 10.1002/cyto.a.22082] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2012] [Revised: 04/12/2012] [Accepted: 05/22/2012] [Indexed: 12/13/2022]
Abstract
Interphase fluorescence in situ hybridization (i-FISH) is a powerful tool for visualizing various molecular targets in non-dividing cells. Manual scoring of i-FISH signals is a labor intensive, time-consuming, and error-prone process liable to subjective interpretation. Automated evaluation of signal patterns provides the opportunity to overcome these difficulties. The first report on automated i-FISH analysis has been published 20 years ago and since then several applications have been introduced in the fields of oncology, and prenatal and fertility screening. In this article, we provide an insight into the automated i-FISH analysis including its course, brief history, clinical applications, and advantages and challenges. The lack of guidelines for describing new automated i-FISH methods hampers the precise comparison of performance of various applications published, thus, we make a proposal for a panel of parameters essential to introduce and standardize new applications and reproduce previously described technologies.
Collapse
Affiliation(s)
- Gábor Pajor
- Department of Pathology, University of Pécs, Medical School, Pécs, Hungary
| | | | | | | |
Collapse
|
6
|
Trakhtenbrot LY. Combined simultaneous analysis of morphology and fluorescence in situ hybridization as a novel sensitive method for detecting small populations of malignant cells in patients with a high risk of cancer, premalignant lesions, and minimal residual disease. RUSS J GENET+ 2010. [DOI: 10.1134/s1022795410100108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
7
|
Trakhtenbrot L, Hardan I, Koren-Michowitz M, Oren S, Yshoev G, Rechavi G, Nagler A, Amariglio N. Correlation between losses ofIGHor its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma. Genes Chromosomes Cancer 2010; 49:17-27. [DOI: 10.1002/gcc.20716] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
|
8
|
Shani T, Onn A, Kabha A, Ben-Dov I, Adam I, Amariglio N, Yahalom R, Rechavi G, Trakhtenbrot L, Hirshberg A. Chromosomal numerical aberrations in apparently normal oral mucosa of heavy smokers affected by lung cancer. Oral Oncol 2009; 46:96-9. [PMID: 20004132 DOI: 10.1016/j.oraloncology.2009.10.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2009] [Revised: 10/25/2009] [Accepted: 10/26/2009] [Indexed: 11/25/2022]
Abstract
Cigarette smoke creates a field of injury in the epithelial lining of the entire respiratory tract causing an increased risk for the development of malignant lesions. It is conceivable, therefore, that early genetic alterations, can be detected in oral mucosa of heavy smokers mainly those affected by lung cancer. As aneuploidy was shown to be an early event in oral carcinogenesis, we aimed to investigate the prevalence of aneuploid cells (ACs) in samples obtained from apparently normal looking oral mucosa of heavy smokers affected by lung cancer (LC). Two brush samples were collected from the oral mucosa of 152 subjects; 31 heavy smokers with LC, 59 heavy smokers without LC and 62 never-smokers. The samples were simultaneously analyzed for morphology and fluorescent in situ hybridization (FISH) using chromosomes 2 and 8 centromeric probes. Over 2% ACs were found in 23% of heavy smokers with LC compared to 12% in heavy smokers without LC and 5% of the never-smokers group (P=0.015). A trend was also noticed when comparing the group of heavy smokers without LC with the never-smokers (P=0.198). We conclude that heavy smokers harbour detectable chromosomal numerical aberrations in oral epithelial cells of normal looking mucosa. These aberrations are more frequently found in heavy smokers affected by LC.
Collapse
Affiliation(s)
- Tali Shani
- Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Yarom N, Shani T, Amariglio N, Taicher S, Kaplan I, Vered M, Rechavi G, Trakhtenbrot L, Hirshberg A. Chromosomal Numerical Aberrations in Oral Lichen Planus. J Dent Res 2009; 88:427-32. [DOI: 10.1177/0022034509337089] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
The malignant potential of oral lichen planus (OLP) has been a matter of serious controversy. We aimed to detect chromosomal numerical aberrations in cells of brush samples collected from affected mucosa. The samples were simultaneously analyzed for morphology and fluorescent in situ hybridization (FISH) with chromosomes 2 and 8 centromeric probes. We analyzed 57 persons with OLP and 33 control individuals. A cut-off value of aneuploid cells was determined as 1.1%. Aneuploid cells were found in 16 persons with OLP (28.1%); in 10 individuals (17.5%), over 5% of the cells were aneuploid. Aneuploid cells were also detected in normal-looking mucosa of seven persons with OLP. One person with OLP developed squamous cell carcinoma; 10% of the cells examined were aneuploid. OLP carries an increased risk for chromosomal instability. Identifying aneuploid cells in a brush sample and the combined morphological and FISH analysis can increase the specificity in predicting the malignant potential of OLP.
Collapse
Affiliation(s)
- N. Yarom
- Department of Oral and Maxillofacial Surgery, The Chaim Sheba Medical Center, Tel Hashomer, Israel
- Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
- Institute of Pathology, Rabin Medical Centre, Beilinson Campus, Petah-Tiqva, Israel; and
- Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel
| | - T. Shani
- Department of Oral and Maxillofacial Surgery, The Chaim Sheba Medical Center, Tel Hashomer, Israel
- Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
- Institute of Pathology, Rabin Medical Centre, Beilinson Campus, Petah-Tiqva, Israel; and
- Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel
| | - N. Amariglio
- Department of Oral and Maxillofacial Surgery, The Chaim Sheba Medical Center, Tel Hashomer, Israel
- Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
- Institute of Pathology, Rabin Medical Centre, Beilinson Campus, Petah-Tiqva, Israel; and
- Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel
| | - S. Taicher
- Department of Oral and Maxillofacial Surgery, The Chaim Sheba Medical Center, Tel Hashomer, Israel
- Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
- Institute of Pathology, Rabin Medical Centre, Beilinson Campus, Petah-Tiqva, Israel; and
- Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel
| | - I. Kaplan
- Department of Oral and Maxillofacial Surgery, The Chaim Sheba Medical Center, Tel Hashomer, Israel
- Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
- Institute of Pathology, Rabin Medical Centre, Beilinson Campus, Petah-Tiqva, Israel; and
- Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel
| | - M. Vered
- Department of Oral and Maxillofacial Surgery, The Chaim Sheba Medical Center, Tel Hashomer, Israel
- Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
- Institute of Pathology, Rabin Medical Centre, Beilinson Campus, Petah-Tiqva, Israel; and
- Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel
| | - G. Rechavi
- Department of Oral and Maxillofacial Surgery, The Chaim Sheba Medical Center, Tel Hashomer, Israel
- Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
- Institute of Pathology, Rabin Medical Centre, Beilinson Campus, Petah-Tiqva, Israel; and
- Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel
| | - L. Trakhtenbrot
- Department of Oral and Maxillofacial Surgery, The Chaim Sheba Medical Center, Tel Hashomer, Israel
- Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
- Institute of Pathology, Rabin Medical Centre, Beilinson Campus, Petah-Tiqva, Israel; and
- Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel
| | - A. Hirshberg
- Department of Oral and Maxillofacial Surgery, The Chaim Sheba Medical Center, Tel Hashomer, Israel
- Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
- Institute of Pathology, Rabin Medical Centre, Beilinson Campus, Petah-Tiqva, Israel; and
- Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
10
|
Erlecke J, Hartmann I, Hoffmann M, Kroll T, Starke H, Heller A, Gloria A, Sayer HG, Johannes T, Claussen U, Liehr T, Loncarevic IF. Automated detection of residual cells after sex-mismatched stem-cell transplantation - evidence for presence of disease-marker negative residual cells. Mol Cytogenet 2009; 2:12. [PMID: 19480690 PMCID: PMC2696465 DOI: 10.1186/1755-8166-2-12] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2009] [Accepted: 05/29/2009] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND A new chimerism analysis based on automated interphase fluorescence in situ hybridization (FISH) evaluation was established to detect residual cells after allogene sex-mismatched bone marrow or blood stem-cell transplantation.Cells of 58 patients were characterized as disease-associated due to presence of a bcr/abl-gene-fusion or a trisomy 8 and/or a simultaneous hybridization of gonosome-specific centromeric probes. The automatic slide scanning platform Metafer with its module MetaCyte was used to analyse 3,000 cells per sample. RESULTS Overall 454 assays of 58 patients were analyzed. 13 of 58 patients showed residual recipient cells at one stage of more than 4% and 12 of 58 showed residual recipient cells less than 4%, respectively. As to be expected, patients of the latter group were associated with a higher survival rate (48 vs. 34 month). In only two of seven patients with disease-marker positive residual cells between 0.1-1.3% a relapse was observed. Besides, disease-marker negative residual cells were found in two patients without relapse at a rate of 2.8% and 3.3%, respectively. CONCLUSION The definite origin and meaning of disease-marker negative residual cells is still unclear. Overall, with the presented automatic chimerism analysis of interphase FISH slides, a sensitive method for detection of disease-marker positive residual cells is on hand.
Collapse
Affiliation(s)
- Jörn Erlecke
- Jena University Hospital, Institute of Human Genetics and Anthropology, Kollegiengasse 10, D-07743 Jena, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Stanchescu R, Betts DR, Rechavi G, Amariglio N, Trakhtenbrot L. Involvement of der(12)t(12;21)(p13;q22) and as well as additional rearrangements of chromosome 12 homolog in ETV6/RUNX1-positive acute lymphoblastic leukemia. ACTA ACUST UNITED AC 2009; 190:26-32. [PMID: 19264230 DOI: 10.1016/j.cancergencyto.2008.12.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2008] [Accepted: 11/20/2008] [Indexed: 12/18/2022]
|
12
|
Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, Paz N, Koren-Michowitz M, Waldman D, Leider-Trejo L, Toren A, Constantini S, Rechavi G. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009; 6:e1000029. [PMID: 19226183 PMCID: PMC2642879 DOI: 10.1371/journal.pmed.1000029] [Citation(s) in RCA: 619] [Impact Index Per Article: 41.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2007] [Accepted: 12/24/2008] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Neural stem cells are currently being investigated as potential therapies for neurodegenerative diseases, stroke, and trauma. However, concerns have been raised over the safety of this experimental therapeutic approach, including, for example, whether there is the potential for tumors to develop from transplanted stem cells. METHODS AND FINDINGS A boy with ataxia telangiectasia (AT) was treated with intracerebellar and intrathecal injection of human fetal neural stem cells. Four years after the first treatment he was diagnosed with a multifocal brain tumor. The biopsied tumor was diagnosed as a glioneuronal neoplasm. We compared the tumor cells and the patient's peripheral blood cells by fluorescent in situ hybridization using X and Y chromosome probes, by PCR for the amelogenin gene X- and Y-specific alleles, by MassArray for the ATM patient specific mutation and for several SNPs, by PCR for polymorphic microsatellites, and by human leukocyte antigen (HLA) typing. Molecular and cytogenetic studies showed that the tumor was of nonhost origin suggesting it was derived from the transplanted neural stem cells. Microsatellite and HLA analysis demonstrated that the tumor is derived from at least two donors. CONCLUSIONS This is the first report of a human brain tumor complicating neural stem cell therapy. The findings here suggest that neuronal stem/progenitor cells may be involved in gliomagenesis and provide the first example of a donor-derived brain tumor. Further work is urgently needed to assess the safety of these therapies.
Collapse
Affiliation(s)
- Ninette Amariglio
- Cancer Research Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
- Institute of Hematology, Sheba Medical Center, Tel Hashomer, Israel
| | - Abraham Hirshberg
- Department of Oral Pathology, School of Dental Medicine, Tel Aviv University, Tel-Aviv, Israel
| | - Bernd W Scheithauer
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America
| | - Yoram Cohen
- Cancer Research Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
| | - Ron Loewenthal
- Tissue Typing Laboratory, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
| | | | - Nurit Paz
- Cancer Research Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
| | | | - Dalia Waldman
- Department of Pediatric Hemato-Oncology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
| | | | - Amos Toren
- Department of Pediatric Hemato-Oncology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
| | - Shlomi Constantini
- Pediatric Neurosurgery, Dana Children's Hospital, Tel-Aviv Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
| | - Gideon Rechavi
- Cancer Research Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
- Department of Pediatric Hemato-Oncology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
- * To whom correspondence should be addressed. E-mail:
| |
Collapse
|
13
|
Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Freiberger A, Lew S, Leibovitch I. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer 2008; 111:517-24. [PMID: 17963263 DOI: 10.1002/cncr.23119] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
BACKGROUND Bladder cancer is among the 5 most common malignancies worldwide. Patients with bladder cancer are closely followed with periodic cystoscopies and urine cytology analyses due to the significant risk of tumor recurrence. The UroVysion fluorescence in situ hybridization (FISH) test demonstrated higher sensitivity over urine cytology in detecting bladder cancer by most comparative studies. METHODS In the current study, the diagnostic usefulness of a combined cytology and FISH analysis approach was tested using the Duet automatic scanning system in patients with benign urine cytology who were being monitored for recurrent urothelial carcinoma or being assessed for various urologic symptoms. RESULTS By combining the benefits of conventional cytology with molecular diagnostics, a more sensitive detection of bladder cancer was attained. All patients who had positive cystoscopy concomitantly with urine sampling were detected by combined analysis. Additional patients that developed transitional cell carcinoma during a follow-up period of 24 months had a previous positive result on combined analysis. Only 2 patients with a negative combined analysis result presented with late disease recurrence (20 months and 22 months, respectively, after the negative test). Therefore, negative combined analysis was found to be predictive of a lack of disease recurrence for at least 12 months. In this timeframe, the overall sensitivity, specificity, negative predictive value (NPV), and positive predictive values of the combined analysis test were 100%, 65%, 100%, and 44%, respectively. CONCLUSIONS Given the absolute sensitivity and NPV of the combined analysis test, the management of patients with a negative combined analysis result might be revised and allow for more flexible assessment and management of bladder cancer patients relying more on urine bound tests.
Collapse
|
14
|
Bedell V, Forman SJ, Gaal K, Pullarkat V, Weiss LM, Slovak ML. Successful application of a direct detection slide-based sequential phenotype/genotype assay using archived bone marrow smears and paraffin embedded tissue sections. J Mol Diagn 2008; 9:589-97. [PMID: 17975026 DOI: 10.2353/jmoldx.2007.070050] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Identification of genetic abnormalities in pathological samples is critical for accurate diagnosis, risk stratification, detection of minimal residual disease, and assessment of response to therapy. Interphase fluorescence in situ hybridization analysis is the standard cytogenetic assay used by many laboratories to detect specific clonal karyotypic aberrations in formalin-fixed, paraffin-embedded tissue. However, direct correlation with immunophenotype or morphology in individual cells is rarely performed because the procedural steps are labor intensive and usually require extensive troubleshooting. In this study, we present a sequential fluorescence in situ hybridization-based technique that uses the identical archived bone marrow smears or paraffin-embedded tissue sections previously evaluated by a pathologist for morphological or immunohistochemical characteristics. This approach is relatively straightforward, using uncomplicated pretreatment and hybridization conditions and basic equipment attached to an automated image analyzer with image capture software to record the location of targeted cells for genotypic/phenotype correlation. Furthermore, the method has proved reliable and reproducible on test samples regardless of specimen age, tissue type, or referring institution.
Collapse
Affiliation(s)
- Victoria Bedell
- Department of Cytogenetics, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA
| | | | | | | | | | | |
Collapse
|
15
|
Koren-Michowitz M, Hardan I, Berghoff J, Yshoev G, Amariglio N, Rechavi G, Nagler A, Trakhtenbrot L. Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: A combined morphology and I-FISH analysis. Cancer Lett 2007; 255:307-14. [PMID: 17590504 DOI: 10.1016/j.canlet.2007.05.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2007] [Revised: 05/04/2007] [Accepted: 05/08/2007] [Indexed: 11/21/2022]
Abstract
Ploidy status and chromosomal aberrations involving chromosome 13q and the immunoglobulin heavy chain locus (IgH) are important prognostic features in multiple myeloma (MM). However, conventional cytogenetic studies are often not reveling and determination of plasma cells (PC) ploidy status in MM is technically difficult. We have used a combined cell morphology and interphase FISH (I-FISH) analysis in 184 consecutive BM samples from 136 MM patients for the diagnosis of chromosome 13q deletion [del (13q)] and IgH abnormalities. We have found a high prevalence (37%) of near-tetraploid (NT) PC in the BM samples studied. NT status of PC was verified with DNA index (DI) measurements. del (13q) was found in 69% and a total absence of one IgH copy (loss of IgH) in 20% of NT samples. We have shown that the presence of del (13q) and loss of IgH can be masked in NT cases: in 12 NT samples originally identified as normal for del (13q) the abnormality was obscured in the majority of plasma cells due to the presence of NT. Similarly, loss of IgH was masked in four samples with a large population of NT cells. Moreover, in one case the appearance of a 100% tetraploidy during disease progression masked the presence of del (13q), originally present, and could therefore falsely appear as disappearance of this prognostic marker. In conclusion, we have shown that a combination of three abnormalities, i.e., del (13q), loss of IgH and NT, all of potential prognostic significance, can be overlooked unless NT is specifically searched for and ruled out. Therefore, we suggest that a search for NT should be added to the routine BM assessment in MM patients.
Collapse
Affiliation(s)
- Maya Koren-Michowitz
- Division of Hematology, The Sheba Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer, Israel.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Vaughan BR, Scott MA, Howard JD, Nacheva EP. Application of growth factor stimulants improves cytogenetic analysis of chronic myeloproliferative disorder patients without alteration to cell lineage or clonality. ACTA ACUST UNITED AC 2007; 175:98-106. [PMID: 17556065 DOI: 10.1016/j.cancergencyto.2007.02.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2006] [Revised: 01/30/2007] [Accepted: 02/08/2007] [Indexed: 10/23/2022]
Abstract
Conventional cytogenetic methods rely on culturing bone marrow aspirates to obtain suitable and sufficient mitotic figures for G-banded analysis. Samples from patients with chronic myeloproliferative disorders (CMPD) often have increased failure rates due to reduced growth and poor morphology, all of which hamper the conventional karyotyping investigation. The application of growth factor (GF) stimulants to bone marrow aspirates has been shown to yield significant increases in both the quality and quantity of bone marrow metaphases obtained in 53 CPMD patient samples. All cultures were stimulated using the conditioned supernatant from the human bladder carcinoma cell line 5637, which contains IL-3, IL-6, and G-CSF. Results were assessed qualitatively on G-banded preparations and quantitatively by mitotic index (MI = % dividing cells). To assess whether the application of GF stimulants leads to clonal selection, culture samples from 15 patients were analyzed by fluorescence in situ hybridization, which supported the theory that clonal selection remains unaltered in GF-stimulated cultures. In addition to this immunophenotyping of cells, we demonstrated the lineage of cells propagated under these conditions. Cell markers were chosen to characterize B-lymphoid, T-lymphoid, myeloid, and primitive cell types. Results indicated that T cells were maintained in culture and B-lymphoid markers remained negative. In the myeloid subset, there was an overall reduction in the pan-myeloid markers. We believe this represents the loss of terminally differentiated cells (e.g., neutrophils) in culture. Overall, the study clearly demonstrates that the application of GF stimulants does not alter clonality or cell lineage propagated in these samples and is therefore suitable for application in diagnostic cytogenetic laboratories.
Collapse
Affiliation(s)
- B R Vaughan
- Department of Academic Haematology, Royal Free and University College London Medical School, Rowland Hill Street, London, NW3 2PF, United Kingdom.
| | | | | | | |
Collapse
|
17
|
Knudson RA, Shearer BM, Ketterling RP. Automated Duet spot counting system and manual technologist scoring using dual-fusion fluorescence in situ hybridization (D-FISH) strategy: comparison and application to FISH minimal residual disease testing in patients with chronic myeloid leukemia. ACTA ACUST UNITED AC 2007; 175:8-18. [PMID: 17498552 DOI: 10.1016/j.cancergencyto.2006.12.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2006] [Revised: 12/19/2006] [Accepted: 12/24/2006] [Indexed: 11/27/2022]
Abstract
The automated BioView Duet system was compared with manual technologist scoring (MTS) using a BCR/ABL dual-fusion FISH (D-FISH) probe strategy for chronic myeloid leukemia (CML) specimens. In the first study, 500 nuclei were evaluated for 10 distinct signal patterns in various abnormal cell percentages from each of 89 specimens. The Duet system correctly identified all 27 normal specimens and the abnormal signal pattern of all 63 abnormal specimens. The percentage of abnormal nuclei detected was also concordant, with an average difference between MTS and the Duet system of only 2.7%. However, achievement of accurate quantitative results required reclassification by a technologist for nearly 50% of nuclei per specimen. Next, the Duet system was used to evaluate BCR/ABL D-FISH for FISH minimal residual disease (MRD) detection in CML patients. Up to 6,000 nuclei were evaluated for four signal pattern categories for each of 60 CML MRD samples. Excluding four abnormal specimens with insufficient samples, the Duet system correctly identified all of the abnormal specimens and identified four additional abnormal specimens previously diagnosed as normal by MTS. The technologist time required for evaluation and reclassification of the Duet system data for the FISH MRD samples averaged only 1 minute per case, saving significant technologist effort. We conclude that the Duet system appears to be more sensitive and cost-effective than MTS for CML FISH MRD testing.
Collapse
MESH Headings
- Diagnosis, Differential
- Fusion Proteins, bcr-abl/genetics
- Humans
- In Situ Hybridization, Fluorescence/instrumentation
- In Situ Hybridization, Fluorescence/methods
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Neoplasm, Residual/diagnosis
- Neoplasm, Residual/genetics
- Reproducibility of Results
- Sensitivity and Specificity
- Time Factors
Collapse
Affiliation(s)
- Ryan A Knudson
- Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
| | | | | |
Collapse
|
18
|
Hirshberg A, Yarom N, Amariglio N, Yahalom R, Adam I, Stanchescu R, Ben-Dov I, Taicher S, Rechavi G, Trakhtenbrot L. Detection of non-diploid cells in premalignant and malignant oral lesions using combined morphological and FISH analysis - a new method for early detection of suspicious oral lesions. Cancer Lett 2007; 253:282-90. [PMID: 17386971 DOI: 10.1016/j.canlet.2007.02.008] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2006] [Revised: 02/02/2007] [Accepted: 02/05/2007] [Indexed: 11/15/2022]
Abstract
Alteration in DNA content is an early event in oral carcinogenesis. We have examined oral brush samples to detect non-diploid cells (NDC) using simultaneous morphological and cytogenetic analysis. The study included 8 oral squamous cell carcinomas (OSCC), 22 premalignant lesions (OPLs), and 25 control individuals. Slides stained with Giemsa followed by FISH using chromosome 2 centromeric DNA probe, were scanned and fluorescent signals were simultaneously analyzed in parallel with the morphology. The proportion of NDC increased with the severity of the diagnosis. In two control subjects, 1-1.5% of the examined cells were NDC. Over 2% NDC were present in all OSCC cases and in 11 of the OPLs, of which, in 8 the histologic diagnosis was either epithelial hyperplasia or mild dysplasia. A significant number of NDC had normal morphology when cytomorphology and FISH were compared. Two patients with OPLs developed OSCC these patients had a significant proportion of NDC. We suggest that the combined morphological and cytogenetic analysis of cells collected by a non-invasive brush sampling can enhance early detection of potentially malignant cells.
Collapse
Affiliation(s)
- Abraham Hirshberg
- Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Trivedi HL, Mishra VV, Vanikar AV, Modi PR, Shah VR, Shah PR, Firoz A. Embryonic stem cell derived and adult hematopoietic stem cell transplantation for tolerance induction in a renal allograft recipient:--a case report. Transplant Proc 2007; 38:3103-8. [PMID: 17112910 DOI: 10.1016/j.transproceed.2006.08.173] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2006] [Indexed: 11/30/2022]
Abstract
UNLABELLED We generated an human embryonic stem cell (hESC) line to augment chimerism-associated tolerance. A 40-year-old African with chronic glomerulonephritis-chronic renal failure with 100% G6PD enzyme deficiency presented for renal transplantation with a 27-year-old, 6/6 HLA-matched sister as a willing donor. METHOD We generated an hESC line from the donor's oocytes using long ovarian stimulation protocol simultaneously with tolerance induction protocol. A nuclear transfer (NT)-hESC line was derived by transferring a donor cumulus cell into an enucleated oocyte, subjected to electrical fusion, and cultured for 5 days. ESCs hatched from the blastocyst on day 6 were cocultured with her unmodified bone marrow for 2 days and suspended in Ringer's lactate. Five milliliters of suspension were collected for cell counting, viability, pluripotency, flow cytometry, and karyotyping. The remaining suspension was infused into the periphery of the recipient. Transplantation was performed 1 week later following a negative lymphocytotoxicity cross-match test using no immunosuppression. Peripheral blood chimerism (PBC) was studied using fluorescent in situ hybridization technique. Allograft biopsy was performed on day 7. RESULTS NT-hESC CD34+ count was 7.6%, viability 100%, karyotyping normal, pluripotency markers: SSEA-1, SSEA-4, OCT-3/4, TRA-1/60:positive; 12% PBC was noted at 1 week after transplantation. Serum creatinine was 1.2 mg%, graft biopsy was unremarkable, and G6PD enzyme deficiency was corrected to 0% at 100 days posttransplant. Liver function tests and hematology profile were unremarkable for graft-versus-host disease. CONCLUSION This is the first report of tolerance induction using NT-hESC-induced hematopoietic chimerism with synergistic use of adult bone marrow. It was safe and effective.
Collapse
Affiliation(s)
- H L Trivedi
- Institute of Transplantation Sciences, Department of Nephrology and Transplantation Medicine, Civil Hospital, Gujarat, India.
| | | | | | | | | | | | | |
Collapse
|
20
|
|
21
|
Lahav M, Uziel O, Kestenbaum M, Fraser A, Shapiro H, Radnay J, Szyper-Kravitz M, Avihai S, Hardan I, Shem-Tov N, Nagler A. Nonmyeloablative conditioning does not prevent telomere shortening after allogeneic stem cell transplantation. Transplantation 2006; 80:969-76. [PMID: 16249747 DOI: 10.1097/01.tp.0000173649.99261.df] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Stem cell transplantation (SCT) may be associated with premature aging of the hematopoietic stem cells. Telomere length reflects the proliferative history of a cell. In most studies published so far on telomere dynamics after myeloablative allogeneic SCT, recipients had shorter telomeres than their respective donors, thus reflecting "accelerated aging" of hematopoietic cells. We evaluated telomere dynamics in patients who underwent transplantation with nonmyeloablative protocols, assuming that the decreased intensity of chemotherapy might prevent telomere attrition. METHODS Telomere length was measured using FISH-FACS method. Telomeres of recipients were compared to their respective donors. Twenty-three consecutive patients after nonmyeloablative SCT were evaluated. A control group consisted of 10 donor-recipient pairs after conventional myeloablative transplantation. RESULTS There was significant telomere shortening in both recipients of nonmyeloablative and myeloablative conditioning (0.487+/-0.65 kb, P=0.003; 0.361+/-0.50 kb, P=0.047 respectively). The extent of telomere shortening in the two groups was not different (P=0.64). There was no correlation between the degree of shortening and parameters such as time interval from transplant, age of donor or recipient, and the number of infused cells. CONCLUSIONS This is the first study on telomere dynamics after nonmyeloablative conditioning SCT. The study demonstrates significant shortening of telomeres in recipients in spite of decreased intensity conditioning. Results of this study suggest that the main mechanism following transplantation is the proliferative stress imposed upon the stem cells and not direct damage by cytotoxic drugs. The different kinetics of restoration of hematopoiesis and the probable ongoing process of graft-versus-leukemia in the bone marrow do not prevent the attrition of telomeric ends of chromosomes.
Collapse
Affiliation(s)
- Meir Lahav
- Medicine A, Rabin Medical Center, Beilinson Campus, Petah-Tikva. Sackler School of Medicine, Tel-Aviv University, Israel.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Zilberstien Y, Friberger A, Kidron D, Kaplan E, Lew S, Leibovitch I. Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples. Urology 2005; 66:1354-9. [PMID: 16360483 DOI: 10.1016/j.urology.2005.07.016] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2005] [Revised: 06/15/2005] [Accepted: 07/11/2005] [Indexed: 11/16/2022]
Abstract
OBJECTIVES To evaluate a combined analysis approach that involves cytologic evaluation and fluorescence in situ hybridization analysis for detecting cancer cells in voided urine samples using an automated scanning station. METHODS Voided urine samples from 41 patients suspected of having transitional cell carcinoma were stained with May-Grünwald Giemsa stain, scanned for atypical or suspicious cells, destained, and hybridized with a mixture of fluorescent-labeled probes. Samples were tested using either the UroVysion probe or by a mix of chromosomes 3, 7, and 17 centromeric probes. A case was regarded as positive when at least one cell was abnormal in both aspects, morphology and fluorescence in situ hybridization. Patients were evaluated concomitantly by cytology, cytoscopy, and biopsy, if indicated. RESULTS Overall, 26 samples were positive by combined analysis. Biopsy-proven transitional cell carcinoma was positive by combined analysis in all cases (100%) and in 13 cases (61.9%) by cytology (P = 0.0133). The advantage of the combined analysis was noted mostly in low-grade and superficial tumors for which the sensitivity of cytology reached 30% (P = 0.023) and 27.27% (P = 0.0133), respectively. Specificity was 100%. CONCLUSIONS Our results have shown that combined analysis for the presence of transitional cell carcinoma cells is a powerful tool, providing high sensitivity and specificity, and may offer a new scheme for bladder cancer management.
Collapse
|
23
|
Karasawa M, Yamane A, Mitsui T, Irisawa H, Sakura T, Matsushima T, Tsukamoto N, Nojima Y, Miyawaki S. Long-term persistence of host cells detected by X-chromosome gene-based assay in patients undergoing gender-mismatched hematopoietic stem cell transplantation. Am J Hematol 2005; 80:101-5. [PMID: 16184584 DOI: 10.1002/ajh.20465] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Using our recently developed human androgen receptor (HUMARA) gene-based chimerism assay, long-term chimerism was investigated in female patients who underwent hematopoietic stem cell transplantation (HCT) with cells from male donors. After restriction digestion of samples, we detected a small number of female-derived cells within a large population of male-derived cells, with a sensitivity from 0.1% to 0.05%. Chimerism was examined in four patients with myeloid malignancies: two patients with acute myeloid leukemia (AML) from myelodysplastic syndrome (MDS), and one patient each with AML M3 and AML M4. All patients underwent myeloablative conditioning regimens and exhibited good clinical results during a median follow-up period of 6.6 years (range, 3.4-7.5 years). Female-derived cells were detected throughout the entire follow-up period in all bone marrow samples, but they became undetectable in the peripheral blood samples of 3 patients. Moreover, the HUMARA band pattern suggests that these residual host cells were normal cells. This study confirms the usefulness of the HUMARA gene-based assay, which showed that patients undergoing HCT frequently show mixed chimerism (MC) for a long period, especially in bone marrow, although the possibility of contamination by host stromal cells cannot be excluded.
Collapse
Affiliation(s)
- Masamitsu Karasawa
- Blood Transfusion Service, University Hospital, Faculty of Medicine, Gunma University, Gunma, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Rothman R, Trakhtenbrot L, Bielorai B, Izraeli S, Ishoev G, Amariglio N, Rechavi G, Toren A. Co-existence of multiple subclones in TEL-AML1 at diagnosis of acute lymphoblastic leukaemia in association with submicroscopic deletion of AML1. Br J Haematol 2005; 129:491-8. [PMID: 15877731 DOI: 10.1111/j.1365-2141.2005.05479.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The TEL/AML1 (ETV6/RUNX1) fusion gene is the most common genetic rearrangement in paediatric acute lymphoblastic leukaemia (ALL). Although considered to be a low-risk leukaemia, it is associated with a relapse rate of 10-20%. The coexistence of different subclones at diagnosis, based on polymerase chain reaction (PCR) studies of IG/TCR gene rearrangement, with differential response to chemotherapy, was recently reported in this subtype of ALL. We wished to demonstrate such subclones at diagnosis by a recently developed technique of quantitative multiparametric fluorescence in situ hybridization (FISH). Bone marrow cells from 80 paediatric patients with ALL at diagnosis were analysed for the presence of the TEL/AML1 fusion gene by interphase FISH. Fourteen patients were positive for the translocation. Four of them had several subclones associated with various combinations of additional chromosomal abnormalities. The most striking was an atypical and unexpected hybridization pattern consistent with a submicroscopic deletion of the 5' region of the AML1 breakpoint. Other abnormalities included TEL deletion, trisomy and tetrasomy 21 as well as double TEL-AML1 fusion. The presence of numerous subclones in about 25% of patients with TEL/AML1+ ALL suggests extensive clonal evolution by the time of diagnosis.
Collapse
Affiliation(s)
- Rachel Rothman
- Department of Paediatric Haemato-Oncology and Institute of Haematology, The Edmond and Lily Safra Children Hospital, The Chaim Sheba Medical Centre, Tel-Hashomer, Israel
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Teuffel O, Betts DR, Thali M, Eberle D, Meyer C, Schneider B, Marschalek R, Trakhtenbrot L, Amariglio N, Niggli FK, Schäfer BW. Clonal expansion of a new MLL rearrangement in the absence of leukemia. Blood 2005; 105:4151-2. [PMID: 15867425 DOI: 10.1182/blood-2005-01-0286] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Kneller A, Cohen N, Berkowicz M, Reichart M, Rosner E, Sokolovski M, Nagler A, Rechavi G, Amariglio N, Trakhtenbrot L. Acquisition of a Ph chromosome with minor BCR/ABL fusion in treatment-related myelodysplastic syndrome with chromosome 7 abnormalities in a patient treated for Hodgkin disease. ACTA ACUST UNITED AC 2005; 159:58-62. [PMID: 15860359 DOI: 10.1016/j.cancergencyto.2004.09.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2004] [Revised: 09/14/2004] [Accepted: 09/15/2004] [Indexed: 10/25/2022]
Abstract
The patient reported in this study originally had Hodgkin disease that was treated heavily with multiple courses of combined chemotherapy and radiotherapy. Secondary myelodysplastic syndrome (MDS) with a complex karyotype with monosomy 7, deletion 7q31, and double deletion 7q31 developed 8 years later. During the course of the disease, conventional cytogenetics and interphase FISH (I-FISH) analysis detected a Ph chromosome and BCR/ABL fusion with mBCR rearrangement. Using a multiparametric cell scanning system that enables combined analysis with probes specific for 7/7q- and BCR/ABL in a single cell, we were able to demonstrate the presence of the BCR/ABL fusion only in cells with monosomy of chromosome 7 and 7q31 deletion, but not in cells with a normal chromosome 7 or with a double deletion of 7q31. We propose two possible models that may explain the appearance of the BCR/ABL fusion in the pre-existing treatment-related MDS clones characterized by chromosome 7 rearrangements.
Collapse
Affiliation(s)
- Abraham Kneller
- Institute of Hematology, The Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Slovak ML, Bedell V, Pagel K, Chang KL, Smith D, Somlo G. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization. ACTA ACUST UNITED AC 2005; 158:99-109. [PMID: 15796956 DOI: 10.1016/j.cancergencyto.2005.01.006] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2004] [Revised: 01/05/2005] [Accepted: 01/10/2005] [Indexed: 11/21/2022]
Abstract
Standard fluorescence in situ hybridization (FISH) easily detects nonrandom karyotypic abnormalities in multiple myeloma (MM) at disease presentation, when tumor burden is high. In contrast, the detection of residual MM using the standard 200 unselected nonmitotic nuclei FISH approach correlates poorly with residual disease detected by morphology, flow cytometry, immunohistochemistry, or reverse-transcription polymerase chain reaction (RT-PCR). We have used sequential May-Grunwald Giemsa stain to identify plasma cell populations, followed by FISH analyses (target FISH or T-FISH) to detect immunoglobulin heavy-chain gene (IGH) rearrangements, 13q or 17p deletions, or hyperdiploidy. In this study, 115 samples were collected from 100 patients with MM regardless of treatment status. In this proof-of-principle prospective study, T-FISH detected MM in 52 samples (45%), a percentage similar to that obtained by pathology. Disease detection increased from 5.6% with standard FISH to 48% with T-FISH, and cell culture experiments showed that T-FISH consistently detected a clonal abnormality at dilutions of 10(-3). In five patients, T-FISH further identified myelodysplastic-associated karyotypic changes restricted to myeloid cells. Our observations suggest that T-FISH identifies cell lineage involvement of cytogenetic abnormalities, improves detection of low-level or residual MM, and may define the coexistence of hematologic karyotypic changes in individual patients.
Collapse
Affiliation(s)
- Marilyn L Slovak
- Division of Pathology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA.
| | | | | | | | | | | |
Collapse
|
28
|
Lev D, Daniely M, Zudik A, Preisler E, Hoffmann N, Kaplan T, Raz U, Yanoov-Sharav M, Vinkler H, Malinger G. Automatic Scanning of Interphase FISH for Prenatal Diagnosis in Uncultured Amniocytes. ACTA ACUST UNITED AC 2005; 9:41-7. [PMID: 15857186 DOI: 10.1089/gte.2005.9.41] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Fluorescence in situ hybridization (FISH) of uncultured amniocytes using chromosome-specific DNA probes offers the opportunity for rapid aneuploidy screening. Between 80 and 95% of all chromosomal disorders expected in the second trimester of pregnancy can be discovered within 24 hr if DNA probes specific for chromosomes 21, 18, 13, X, and Y are used. Rapid results are crucial for clinical decision-making and are helpful in decreasing the anxiety level in most patients. One of the major factors that have been preventing the rapid FISH test from being broadly incorporated into the clinical setting is the limited staff in the cytogenetics laboratories. The present study demonstrates the use of an automated scanning system (Duet, BioView Ltd. Rehovot, Israel) for analyzing FISH in uncultured amniocytes. Fifty-six amniotic fluid samples were evaluated in parallel by karyotyping, manual FISH analysis, and automatic FISH scanning. Automatic scanning provided accurate results compared to both manual FISH scoring and karyotype analysis. The correlation between automatic and manual FISH scanning was found to be very high (r = 0.9, p < 0.0001). The availability of automation for aneuploidy screening in amniotic fluid samples will enable offering this test to a broader patient population while providing fast and reliable results.
Collapse
Affiliation(s)
- Dorit Lev
- Institute for Medical Genetics, Wolfson Medical Center, Holon, 58100, Israel
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Raanani P, Ben-Bassat I, Gan S, Trakhtenbrot L, Mark Z, Ashur-Fabian O, Itskovich S, Brok-Simoni F, Rechavi G, Amariglio N, Nagler A. Assessment of the response to imatinib in chronic myeloid leukemia patients - comparison between the FISH, multiplex and RT-PCR methods. Eur J Haematol 2004; 73:243-50. [PMID: 15347310 DOI: 10.1111/j.1600-0609.2004.00287.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE The objective of this study was to evaluate the kinetics of molecular response in chronic myeloid leukemia (CML) patients treated with imatinib and to compare between the fluorescent in situ hybridization (FISH), multiplex and real-time quantitative RT-PCR (RQ-PCR) methods with this respect. METHODS Molecular follow-up was carried out on 24 CML patients treated with imatinib. FISH analysis was performed according to the standard protocol. For RT-PCR the multiplex and RQ-PCR methods were used. RESULTS Sixty-three percent and 52% of the patients achieved complete remission according to FISH and multiplex RT-PCR analyses, respectively. Seventy-five percent of the patients achieved remission within the first year of treatment. In 83% of the cases the FISH and RT-PCR results were concordant. RQ-PCR analysis was carried out on 32 of the 41 samples negative by multiplex RT-PCR but only nine were negative. All samples with a BCR-ABL/ABL ratio below 2% were also negative by FISH. There was an excellent correlation between the RQ-PCR and the FISH tests. CONCLUSIONS Molecular remission according to FISH and multiplex RT-PCR can be achieved by imatinib within 1 yr of therapy. There is a good correlation between the FISH, multiplex and RQ-PCR results in terms of the kinetics of disappearance of the BCR-ABL transcript and the predictability of each method for the other. Although RQ-PCR is the most sensitive method for molecular follow-up, FISH and multiplex RT-PCR can be used as complementary tools, at least during the early period of treatment.
Collapse
MESH Headings
- Adult
- Aged
- Antineoplastic Agents/therapeutic use
- Benzamides
- Female
- Humans
- Imatinib Mesylate
- In Situ Hybridization, Fluorescence/methods
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Male
- Middle Aged
- Piperazines/therapeutic use
- Pyrimidines/therapeutic use
- Remission Induction
- Reverse Transcriptase Polymerase Chain Reaction/methods
Collapse
Affiliation(s)
- Pia Raanani
- The Institute of Hematology, The Chaim Sheba Medical Center, Tel-Hashomer, Israel.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Izraeli S, Waldman D. Minimal residual disease in childhood acute lymphoblastic leukemia: current status and challenges. Acta Haematol 2004; 112:34-9. [PMID: 15179003 DOI: 10.1159/000077558] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The pace of disappearance of leukemic blasts in response to therapy has long been recognized as the most important prognostic factor in childhood acute lymphoblastic leukemia (ALL). Recent technological advancements enable detection of submicroscopic leukemic cells. The extent of reduction in the level of minimal residual disease (MRD) during the first phase of therapy can be exploited for improved risk classification of children with ALL. Current prospective studies test the hypothesis that tailoring treatment to the level of MRD will improve patients' outcome.
Collapse
Affiliation(s)
- Shai Izraeli
- Department of Pediatric Hemato-Oncology and the Cancer Research Center, Safra Children Hospital, Sheba Medical Center, Tel Hashomer, Israel.
| | | |
Collapse
|
31
|
Bielorai B, Trakhtenbrot L, Amariglio N, Rothman R, Tabori U, Dallal I, Golan H, Neumann Y, Reichart M, Kaplinsky C, Rechavi G, Toren A. Multilineage hematopoietic engraftment after allogeneic peripheral blood stem cell transplantation without conditioning in SCID patients. Bone Marrow Transplant 2004; 34:317-20. [PMID: 15220954 DOI: 10.1038/sj.bmt.1704565] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Successful stem cell transplantation for patients with severe combined immunodeficiency (SCID) from matched family donors without conditioning results in engraftment of T lymphocytes. B lymphocytes engraft in only 50% of the cases, while myelopoiesis and erythropoiesis remain of host origin. Full hematopoietic engraftment was reported in one case after bone marrow transplantation without conditioning for a SCID patient. We studied three SCID patients who were transplanted with unmodified mobilized peripheral blood from HLA-identical family sex-mismatched members. They received megadoses of stem cells (18-23 x 10(6)CD34/kg). In contrast to the expected mixed chimerism that usually occurs in the absence of conditioning, we found in our patients 100% donor cell engraftment based on fluorescence in situ hybridization (FISH) and microsatellite techniques. Subset analysis of the engrafted cells using a multiparametric system enabling a combined analysis of morphology, immunophenotyping and FISH showed that both T and B lymphocytes and myeloid cells were of donor origin in two patients, while T lymphocytes and myeloid cells were of donor origin in the third. In the two cases with ABO incompatibility, erythroid engraftment was evidenced by blood group conversion from recipient to donor type. Multilineage donor engraftment is possible in SCID patients even without conditioning.
Collapse
Affiliation(s)
- B Bielorai
- Department of Pediatric Hematology-Oncology and BMT and the Institute of Hematology, Sheba Medical Center, Tel-Hashomer, affiliated to the Sackler School of Medicine, Tel-Aviv University, Israel.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Trakhtenbrot L, Rechavi G, Amariglio N. The multiparametric scanning system for evaluation of minimal residual disease in hematological malignancies. Acta Haematol 2004; 112:24-9. [PMID: 15179001 DOI: 10.1159/000077556] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Combined simultaneous analysis of morphology, immunophenotyping and fluorescence in situ hybridization on the same cell offers advantages that may help to disclose the relevance of minimal residual disease (MRD) detection. Morphological analysis of small populations of cells related either to malignancy or recipient-associated markers may improve the accuracy of chimerism and MRD testing and delineate their clinical significance.
Collapse
Affiliation(s)
- Luba Trakhtenbrot
- Department of Pediatric Hematology-Oncology, Safra Children's Hospital and Institute of Hematology, The Chaim Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
| | | | | |
Collapse
|
33
|
Shimoni A, Nagler A. Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning. Acta Haematol 2004; 112:93-104. [PMID: 15179009 DOI: 10.1159/000077564] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Allogeneic stem cell transplantation (SCT) is a potentially curative therapy for a variety of hematological malignancies; however, relapse and treatment-related toxicities are major obstacles to cure. Nonmyeloablative and reduced-intensity conditioning regimens were designed not to eradicate the malignancy completely, but rather to be immunosuppressive enough to allow engraftment, and to serve as a platform for additional cellular immunotherapy. Minimal residual disease (MRD) typically persists after SCT, and is gradually eliminated with different kinetics typical of each disease. Significant progress has been achieved with technologies for MRD assessment. Quantitative PCR tests are very sensitive in detecting tumor-associated transcripts, allowing serial monitoring. Threshold levels have been established for some malignancies, above which relapse is imminent. Persistent negative tests, a low level or a decreasing MRD level are consistent with continuous remission, whereas high-level MRD or increasing levels predict an incipient relapse. Patients at high risk of relapse are candidates for additional cellular or targeted therapy. Immunotherapy is more effective for MRD than at frank relapse. Timing and dosing of therapy are not yet well established and depend on aggressiveness of the disease, type of conditioning, level and kinetics of MRD.
Collapse
Affiliation(s)
- Avichai Shimoni
- Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel.
| | | |
Collapse
|
34
|
Hardan I, Rothman R, Gelibter A, Cohen N, Shimoni A, Sokolovsky M, Reichart M, Ishoev G, Amariglio N, Rechavi G, Nagler A, Trakhtenbrot L. Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis. Exp Hematol 2004; 32:254-60. [PMID: 15003310 DOI: 10.1016/j.exphem.2003.12.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2003] [Revised: 11/13/2003] [Accepted: 12/17/2003] [Indexed: 10/26/2022]
Abstract
Deletion of chromosome 13q is believed to be an adverse prognostic marker in patients with multiple myeloma (MM). Interphase fluorescence in situ hybridization (I-FISH) is the method of choice for detection of chromosome 13q deletion (del13q). However, I-FISH has high false-positive rates attributed to a low percentage of plasma cells (PC), which are responsible for MM, in bone marrow (BM) samples from MM patients. In an attempt to overcome this problem, combined morphologic and I-FISH analyses were performed by a unique system that allows rapid automatic scanning of a large number of cells with simultaneous determination of the lineage of specific cells carrying del13q. The percentage of PC with del13q in BM samples from 40 MM patients was calculated. In addition, we established a useful prognostic ratio defined as the number of PC with del13q divided by the number of non-PC with del13q (PDP/PDNP), which may help to precisely define the putative role of del13q in prediction response of MM patients to new therapeutic compounds. We suggest this technique as a novel sensitive and specific method for detection of del13q in a minor PC population of MM patients.
Collapse
Affiliation(s)
- Izhar Hardan
- Department of Bone Marrow Transplantation, Hematology and the Sheba Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Chou PM, Olszewski M, Huang W, Silva M, Kletzel M. Platelet chimerism by polymerase chain reaction (PCR) utilizing variable number of tandem repeats (VNTR) in allogeneic stem cell transplant in children: a new novel approach to full chimerism analysis. Bone Marrow Transplant 2003; 32:825-8. [PMID: 14520429 DOI: 10.1038/sj.bmt.1704236] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Evaluation of chimerism following allogeneic transplantation has been performed traditionally focusing on two cellular compartments, namely lymphoid and myeloid. However, none has been described so far to evaluate platelet chimerism. In order to achieve full chimerism in all three cellular compartments, we prospectively obtained 138 samples of peripheral blood in 55 patients at different post transplant periods following allogeneic hematopoietic transplantation. Evaluation of chimerism was performed utilizing tests of variable number of tandem repeat (VNTR) and sex determination by quantitative polymerase chain reaction (PCR). Tests for platelet chimerism using platelet-rich plasma were simultaneously analyzed with samples for T-cell lymphoid and myeloid compartments. Complete donor chimerism was noted in 49 of 55 patients (89%), while the remaining six have split chimerism ranging from 34 to 98%. There is significant difference (P=0.0004) between the percentages of donor DNA in all three cellular compartments comparing the means+/-s.e.m. (myeloid 95.60+/-0.9, T-cell lymphocytes 87.6+/-1.9, and the platelets 90.8+/-1.5); however, comparison between the medians is not statistically significant. This study represents an additional step towards achieving full chimerism and the observation may help reduce the number of unnecessary platelet transfusions once chimerism is noted in that cellular compartment.
Collapse
Affiliation(s)
- P M Chou
- Department of Pathology, Children's Memorial Hospital, Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60614, USA.
| | | | | | | | | |
Collapse
|
36
|
Wu CJ, Hochberg EP, Rogers SA, Kutok JL, Biernacki M, Nascimento AF, Marks P, Bridges K, Ritz J. Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Exp Hematol 2003; 31:924-33. [PMID: 14550808 DOI: 10.1016/s0301-472x(03)00227-3] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
OBJECTIVE Nonmyeloablative conditioning regimens for allogeneic stem cell transplantation are now commonly used in the treatment of patients with hematologic malignancies. Since this treatment often results in the establishment of mixed hematopoietic chimerism, this approach may also prove to be useful in the treatment of nonmalignant disorders, such as sickle cell disease and thalassemia major. To apply this approach to these diseases, it will be necessary to determine the levels of donor erythropoiesis required to correct hemolysis and ameliorate disease symptoms. Current methods for measuring hematopoietic chimerism are based on DNA polymorphisms that distinguish recipient from donor. These methods accurately measure donor leukocyte engraftment but do not quantify the relative contributions of recipient and donor erythropoiesis following transplant. METHODS To specifically measure erythroid-lineage chimerism, we used pyrosequencing of the sickle cell mutation to quantify the relative levels of normal and sickle beta-globin mRNA in patient samples. Results of beta-globin RNA chimerism were compared to assessment of beta-globin DNA chimerism as well as analysis of short tandem repeat (STR) polymorphisms, cytogenetics, and hemoglobin electrophoresis. RESULTS Donor engraftment was measured in two adult patients following nonmyeloablative stem cell transplant for sickle cell disease. In Patient 1, 25 to 30% of peripheral leukocytes were donor derived after day 41. In contrast, more than 55% of peripheral blood beta-globin mRNA was of donor origin, and these results correlated with posttransplant clinical improvement. Patient 2 achieved 40 to 50% donor leukocyte engraftment from day 33 onward. This was associated with 70 to 100% peripheral blood donor beta-globin mRNA. CONCLUSIONS These studies demonstrate that relatively low levels of donor leukocyte engraftment can be associated with higher levels of donor erythropoiesis and with significant clinical improvement. Pyrosequencing of lineage-specific mRNA directly measures functional reconstitution of donor cells and provides valuable information that can affect clinical decisions in patients with nonmalignant diseases following allogeneic transplant.
Collapse
Affiliation(s)
- Catherine J Wu
- Departments of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A, Amariglio N, Rechavi G, Izraeli S. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32:31-4. [PMID: 12815475 DOI: 10.1038/sj.bmt.1703902] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is frequently used to mobilize CD34+ cells in healthy donors and patient with malignant diseases prior to peripheral blood stem cell (PBSC) harvest. To analyze the effects of rhG-CSF on morphology and genotype of white blood cells, a novel multiparametric cell scanning system that combines morphologic, immune and genotypic analyses of the same cells was used. We report here that tetraploid myeloid cells are present in the peripheral blood of donors treated with rhG-CSF. The tetraploidy was detected in up to 0.6% of differentiated myeloid cells and all observed CD34+ cells were diploid. Thus, short treatment with rhG-CSF of PBSC donors induces numerfical chromosomal alterations in a small subset of mature myeloid cells.
Collapse
Affiliation(s)
- C Kaplinsky
- Department of Pediatric Hemato-Oncology, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
| | | | | | | | | | | | | | | | | |
Collapse
|